HB-201 + HB-202

HB-201 + HB-202 is an investigational immunotherapy for the treatment of Human Papillomavirus (HPV) 16-positive cancers, particularly HPV-associated head and neck squamous cell carcinoma (HNSCC) and other solid tumors. This therapy consists of two gene-modified arenavirus-based vectors—HB-201 (based on lymphocytic choriomeningitis virus [LCMV]) and HB-202 (based on Pichinde virus [PICV])—administered in an alternating regimen. Both vectors express a non-oncogenic but highly immunogenic fusion protein derived from the E6 and E7 antigens of HPV16. The mechanism of action involves stimulating a robust CD8+ T cell-mediated immune response against tumor cells expressing these viral antigens. Preclinical studies have shown that sequential administration induces higher levels of tumor-specific CD8+ T cells than either agent alone. Clinical trials have demonstrated preliminary safety and antitumor activity in heavily pre-treated patients with HPV16+ cancers[1][2][3][4][5][6].

Other names

TheraTalternating 2-vector therapyalternating2-vector therapyalternating-2-vector therapyHPV16 E6/E7 encoding arenavirus vaccine